advertisement
Abstract #16800 Published in IGR 9-1
Deep sclerectomy with mitomycin C in failed trabeculectomy
Rebolleda G; Munoz-Negrete FJEye 2007; 21: 23-28
AIM: To evaluate the success rate and complications associated with deep sclerectomy with mitomycin C (MMC) and a reticulated hyaluronic acid implant in previously failed trabeculectomy. METHODS: This prospective study included 20 eyes with a previously failed trabeculectomy, which were treated with deep sclerectomy with 0.2 mg/ml MMC application under the conjunctiva and superficial scleral flap. Intraocular pressure (IOP), glaucoma medications, visual acuity, and complications were recorded preoperatively and 1 day, 1 week, and 1, 3, 6, and 12 months postoperatively. RESULTS: The mean preoperative IOP was 25.8 ± 7.3 mmHg; the IOP significantly decreased to 14.6 ± 3.2 mmHg 1 year postoperative. At each interval, the mean IOP was significantly lower than preoperatively (P = 0.000). At 1 year, the complete success rate (IOP ≤ 21 mmHg untreated) was 65% and the qualified success rate (IOP ≤ 21 mmHg with and without medication) was 100%. 12 patients (60%) achieved an IOP ≤1 5 mmHg with and without medication. No shallow or flat anterior chamber, endophthalmitis, or leakage developed. CONCLUSIONS: These data suggest that deep sclerectomy augmented with MMC is a safe surgical procedure that decreases IOP in eyes with a previously failed trabeculectomy.
Dr. G. Rebolleda, Glaucoma Unit, Ophthalmology Department, Hospital Ramon y Cajal, University of Alcala, Madrid, Spain. grebolleda@telefonica.net
Classification:
12.8.3 Non-perforating (Part of: 12 Surgical treatment > 12.8 Filtering surgery)
12.8.10 Woundhealing antifibrosis (Part of: 12 Surgical treatment > 12.8 Filtering surgery)
